Axovia Therapeutics

Axovia is excited to announce a new joint research collaboration with @Rhythm Pharmaceuticals to advance the understanding of #BardetBiedlSyndrome. Read more https://lnkd.in/egx6hKAH

Our CEO, Prof Phil Beales, recently sat down for a webinar with two experts in ophthalmology and obesity management to discuss #Bardet-BiedlSyndrome. Guest speakers Brittni A. Scruggs, M.D., Ph.D. from the Mayo Clinic, Minnesota and Jesse Richards, DO, of OU Health, Oklahoma, shared their experience treating patients and reviewed the current standard of care. Please click https://lnkd.in/eGkZM2bf to tune in and learn more!

Our CEO, Professor Phil Beales, will be in London next week on Tuesday, October 15th to present a company overview at the European Cell & Gene Therapy Summit 2024. We hope you will reach out if you would like to connect and we hope to see you there!

Our CEO, Professor Phil Beales, will present a company overview tomorrow, October 1st at 3:15 p.m. ET at the Chardan Annual Genetic Medicines Conference. Join him to learn more about Axovia’s work advancing new therapies for genetic forms of obesity and blindness. 

Cilia2024 is coming up! Cilia2024 is a biennial Europe-based international cilia research meeting, taking place this year on September 10-13th in Dublin, Ireland. We are very pleased to see the growth of this meeting over the last 12 years. It has evolved into the world’s largest scientific meeting for cilia and flagella research and always invites and provides for the patient voice. Axovia is a sponsor this year and our CEO & Co-Founder, Prof Phil Beales, will be addressing the ciliopathy patient community attending the conference. We look forward to the opportunity to connect with researchers, clinicians, patients and patient representatives onsite next week!  #Cilia2024 #CiliaResearch #PatientVoice #AxoviaTherapeutics

Proud moment for Axovia Therapeutics! Our Chief Scientific Officer, Dr Victor Hernandez, delivered an insightful presentation on the first gene therapy for the prevention of blindness in Bardet-Biedl Syndrome (BBS) at The Global Cell & Gene Therapy Summit 2024. #BardetBiedlSyndrome #CellAndGeneTherapy #Innovation #GlobalSummit #AxoviaTherapeutics #Leadership #ScientificExcellence

Our CEO, Professor Phil Beales, will give a talk titled, “Update on Research and Study of BBS” at the upcoming BBS UK conference being held virtually this Saturday, June 8th. We hope to see you there!   #BardetBiedlSyndrome #axoviatherapeutics

The Axovia team attended #ASGCT24 last week and presented a poster highlighting preclinical data supporting lead program AXV-101 for treatment of blindness associated with BBS1 mutations. AXV-101 has the potential to address blindness and obesity associated with Bardet-Biedl Syndrome (BBS) and will begin clinical studies in 1H25. #axoviatherapeutics #genetherapy

🔬 Exciting News from Axovia Therapeutics! 🔬 We are thrilled to announce the presentation of promising preclinical data for our lead program, AXV-101, at ASGCT. AXV-101 is designed to address blindness associated with BBS1 mutations, offering hope to those affected by this challenging condition. https://lnkd.in/eqi8eAtA #ASGCT #AxoviaTherapeutics #BlindnessTreatment #GeneticTherapy #InnovationInMedicine